All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), ipilimumab based treatment vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EORTC 18071, 2015 0.72 [0.58; 0.89]
0.72 [0.58 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable deaths (OS) (extension)detailed results EORTC 18071, 2015 0.73 [0.64; 0.83]
0.73 [0.64 ; 0.83 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFSdetailed results EORTC 18071, 2015 0.76 [0.63; 0.91]
0.76 [0.63 ; 0.91 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable RFS (extension)detailed results EORTC 18071, 2015 0.75 [0.63; 0.89]
0.75 [0.63 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable RFS/DFSdetailed results EORTC 18071, 2015 0.75 [0.63; 0.89]
0.75 [0.63 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable AE (any grade)detailed results EORTC 18071, 2015 7.53 [3.17; 17.90]
7.53 [3.17 ; 17.90 ] EORTC 18071, 2015 1 0% 945 NA not evaluable AE (grade 3-4)detailed results EORTC 18071, 2015 0.11 [0.08; 0.17]
0.11 [0.08 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE (any grade)detailed results EORTC 18071, 2015 14.40 [10.07; 20.60]
14.40 [10.07 ; 20.60 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE (grade 3-4)detailed results EORTC 18071, 2015 25.27 [14.14; 45.18]
25.27 [14.14 ; 45.18 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE leading to death (grade 5)detailed results EORTC 18071, 2015 10.16 [0.55; 186.52]
10.16 [0.55 ; 186.52 ] EORTC 18071, 2015 1 0% 945 NA not evaluable TRAE leading to discontinuation (any grade)detailed results EORTC 18071, 2015 21.35 [13.41; 33.97]
21.35 [13.41 ; 33.97 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 39.14 [5.34; 286.74]
39.14 [5.34 ; 286.74 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results EORTC 18071, 2015 25.54 [6.16; 105.87]
25.54 [6.16 ; 105.87 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.70 [5.84; 312.15]
42.70 [5.84 ; 312.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 22.61 [8.20; 62.34]
22.61 [8.20 ; 62.34 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 57.44 [7.90; 417.44]
57.44 [7.90 ; 417.44 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 44.19 [2.67; 732.31]
44.19 [2.67 ; 732.31 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results EORTC 18071, 2015 18.45 [1.07; 319.15]
18.45 [1.07 ; 319.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Rash TRAE (grade 3-4)detailed results EORTC 18071, 2015 10.16 [0.55; 186.52]
10.16 [0.55 ; 186.52 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.00 [2.53; 697.02]
42.00 [2.53 ; 697.02 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Abdominal pain AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.17]
0.04 [0.01 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Cough AE (grade 3-4)detailed results Out of scale EORTC 18071, 2015 0.01 [0.00; 0.15]
0.01 [0.00 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.01; 0.46]
0.06 [0.01 ; 0.46 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EORTC 18071, 2015 0.26 [0.18; 0.37]
0.26 [0.18 ; 0.37 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Fatigue AE (grade 3-4)detailed results EORTC 18071, 2015 0.05 [0.03; 0.10]
0.05 [0.03 ; 0.10 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Headache AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.11]
0.04 [0.01 ; 0.11 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results EORTC 18071, 2015 0.80 [0.45; 1.45]
0.80 [0.45 ; 1.45 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increased ALT AE (grade 3-4)detailed results EORTC 18071, 2015 0.97 [0.55; 1.70]
0.97 [0.55 ; 1.70 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nausea AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pruritus AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.07; 0.26]
0.14 [0.07 ; 0.26 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pyrexia AE (grade 3-4)detailed results EORTC 18071, 2015 0.21 [0.08; 0.56]
0.21 [0.08 ; 0.56 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Rash AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.03; 0.15]
0.06 [0.03 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Vomiting AE (grade 3-4)detailed results EORTC 18071, 2015 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Weight decreased AE (grade 3-4)detailed results EORTC 18071, 2015 0.02 [0.00; 0.16]
0.02 [0.00 ; 0.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 09:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 850,329,558,579,549,868